AU2003208888B2 - Uses of mammalian cytokine; related reagents - Google Patents

Uses of mammalian cytokine; related reagents Download PDF

Info

Publication number
AU2003208888B2
AU2003208888B2 AU2003208888A AU2003208888A AU2003208888B2 AU 2003208888 B2 AU2003208888 B2 AU 2003208888B2 AU 2003208888 A AU2003208888 A AU 2003208888A AU 2003208888 A AU2003208888 A AU 2003208888A AU 2003208888 B2 AU2003208888 B2 AU 2003208888B2
Authority
AU
Australia
Prior art keywords
leu
ser
thr
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003208888A
Other languages
English (en)
Other versions
AU2003208888A1 (en
Inventor
Rene De Waal Malefyt
Yong-Jun Liu
Marehalli L Nagalakshmi
Vassili Soumelis
Norihiko Watanabe
Wei Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27734298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003208888(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of AU2003208888A1 publication Critical patent/AU2003208888A1/en
Application granted granted Critical
Publication of AU2003208888B2 publication Critical patent/AU2003208888B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: SCHERING CORPORATION
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003208888A 2002-02-01 2003-01-30 Uses of mammalian cytokine; related reagents Expired AU2003208888B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35350902P 2002-02-01 2002-02-01
US60/353,509 2002-02-01
PCT/US2003/002758 WO2003065985A2 (en) 2002-02-01 2003-01-30 Uses of mammalian cytokine; related reagents

Publications (2)

Publication Number Publication Date
AU2003208888A1 AU2003208888A1 (en) 2003-09-02
AU2003208888B2 true AU2003208888B2 (en) 2006-10-19

Family

ID=27734298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003208888A Expired AU2003208888B2 (en) 2002-02-01 2003-01-30 Uses of mammalian cytokine; related reagents

Country Status (11)

Country Link
US (5) US20030186875A1 (cg-RX-API-DMAC7.html)
EP (3) EP2311869B2 (cg-RX-API-DMAC7.html)
JP (4) JP2005516606A (cg-RX-API-DMAC7.html)
AU (1) AU2003208888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2474011C (cg-RX-API-DMAC7.html)
DK (1) DK2311869T3 (cg-RX-API-DMAC7.html)
ES (1) ES2399503T5 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007426A (cg-RX-API-DMAC7.html)
NZ (1) NZ533987A (cg-RX-API-DMAC7.html)
PT (1) PT2311869E (cg-RX-API-DMAC7.html)
WO (1) WO2003065985A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
CA2349762C (en) * 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
EP1651247B1 (en) 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
ES2385450T3 (es) * 2004-03-22 2012-07-25 Osiris Therapeutics, Inc. Células madre mesenquimatosas y sus utilizaciones
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) * 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
BRPI0907501B1 (pt) 2008-02-01 2021-02-23 Ceres, Inc construto de vetor, método para dirigir a transcrição, método de expressão de uma região de codificação exógena, método de alteração da expressão de um gene e método de produção de uma planta transgênica
US12331304B2 (en) 2008-02-01 2025-06-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and uses thereof
EP2213682A1 (en) * 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
JP2012032655A (ja) * 2010-07-30 2012-02-16 Fujimori Sangyo Kk ホログラム付きラミネートフィルム及びその製造方法、これを用いた容器
JP2015502917A (ja) * 2011-10-28 2015-01-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Tslp処置のバイオマーカーとしてのil−19
EP2773774A4 (en) 2011-11-03 2015-06-10 Merck Sharp & Dohme BIOMARKERS FOR TSLP TREATMENT
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017362A1 (en) * 1998-09-21 2000-03-30 Schering Corporation Human interleukin-b50, therapeutic uses
WO2001012672A2 (en) * 1999-08-18 2001-02-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2349762C (en) * 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
US7067712B2 (en) * 2000-06-16 2006-06-27 Hitoshi Mizutani Caspase 1 gene transfer animal
EP1297017B1 (en) * 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
WO2002000723A2 (en) * 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017362A1 (en) * 1998-09-21 2000-03-30 Schering Corporation Human interleukin-b50, therapeutic uses
WO2001012672A2 (en) * 1999-08-18 2001-02-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Reche, P. et al., Journal of Immunology, 2001, vol 167, pages 336-343 *

Also Published As

Publication number Publication date
DK2311869T3 (da) 2013-03-18
EP2311869A1 (en) 2011-04-20
EP2077277A1 (en) 2009-07-08
AU2003208888A1 (en) 2003-09-02
US20100136003A1 (en) 2010-06-03
WO2003065985A3 (en) 2004-10-14
JP2009132730A (ja) 2009-06-18
WO2003065985A2 (en) 2003-08-14
JP2014156478A (ja) 2014-08-28
US20110229434A1 (en) 2011-09-22
EP2311869B1 (en) 2012-12-19
ES2399503T5 (es) 2021-04-08
US20030186875A1 (en) 2003-10-02
JP2005516606A (ja) 2005-06-09
EP1487865A4 (en) 2005-12-14
US20070020262A1 (en) 2007-01-25
PT2311869E (pt) 2013-03-04
EP1487865A2 (en) 2004-12-22
MXPA04007426A (es) 2004-10-11
ES2399503T3 (es) 2013-04-01
CA2474011A1 (en) 2003-08-14
NZ533987A (en) 2007-04-27
JP2012184259A (ja) 2012-09-27
CA2474011C (en) 2014-03-25
EP2311869B2 (en) 2020-06-17
JP5519946B2 (ja) 2014-06-11
US20090017018A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
CA2474011C (en) Use of the mammalian cytokine, tslp/il-50, for modulating dendritic cell activity and treatment of immune disorders
Takatsu Interleukin-5 and IL-5 receptor in health and diseases
KR100895749B1 (ko) Nkg2d의 조절
US20060039910A1 (en) Methods and compositions for treating allergic inflammation
TW201833326A (zh) Cd70結合分子及使用彼之方法
JP2003524644A (ja) Cd40−結合性apc−活性化分子
AU2006214325B2 (en) Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
EP2292760A2 (en) Mammalian cytokines, receptors, related reagents and methods
KR20210149050A (ko) T 세포 수용체 및 이의 사용 방법
Teng et al. Characterization of chicken interleukin 2 receptor α chain, a homolog to mammalian CD25
CA2454185A1 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2011038689A1 (zh) 人类新细胞因子VSTM1-v2及其应用
US8246959B1 (en) Dendritic cell-associated lectin-like molecules, compositions and methods of use
US20040052782A1 (en) Costimulatory molecules and uses thereof
CA2231433A1 (en) Method for modulating cell apoptosis
WO2003086457A2 (en) Method of treating or preventing autoimmune disease
Pure et al. Role of Cell Adhesion Molecules in T Cell-Myocyte Interactions in Airway Inflammation.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ MERCK SHARP & DOHME CORP. .

HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired